دورية أكاديمية
أعرض في EDS

RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.

التفاصيل البيبلوغرافية
العنوان: RBD design increases the functional antibody titers elicited by SARS-CoV-2 spike vaccination.
المؤلفون: Dickey TH; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Salinas ND; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Patel P; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Orr-Gonzalez S; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Ouahes T; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., McAleese H; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Richardson BL; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Singleton M; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Murphy M; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, MD, 21702, USA., Eaton B; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, MD, 21702, USA., Kwan JL; Epidemiology and Population Studies Unit, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Holbrook MR; Integrated Research Facility, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Frederick, MD, 21702, USA., Lambert LE; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA., Tolia NH; Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD, 20894, USA. Electronic address: niraj.tolia@nih.gov.
المصدر: Antiviral research [Antiviral Res] 2024 Aug; Vol. 228, pp. 105937. Date of Electronic Publication: 2024 Jun 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: Netherlands NLM ID: 8109699 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-9096 (Electronic) Linking ISSN: 01663542 NLM ISO Abbreviation: Antiviral Res Subsets: MEDLINE
أسماء مطبوعة: Publication: Amsterdam : Elsevier
Original Publication: [Amsterdam ; New York : Elsevier/North-Holland Biomedical Press, c1981-
مواضيع طبية MeSH: Spike Glycoprotein, Coronavirus*/immunology , COVID-19 Vaccines*/immunology , Antibodies, Neutralizing*/immunology , Antibodies, Neutralizing*/blood , Antibodies, Viral*/immunology , Antibodies, Viral*/blood , SARS-CoV-2*/immunology , COVID-19*/immunology , COVID-19*/prevention & control, Animals ; Mice ; Humans ; Vaccination ; Female ; Protein Domains/immunology
مستخلص: Most COVID-19 vaccines contain the SARS-CoV-2 spike protein as an antigen, but they lose efficacy as neutralizing antibody titers wane and escape variants emerge. Modifying the spike antigen to increase neutralizing antibody titers would help counteract this decrease in titer. We previously used a structure-based computational design method to identify nine amino acid changes in the receptor-binding domain (RBD) of spike that stabilize the RBD and increase the neutralizing antibody titers elicited by vaccination. Here, we introduce those enhancing amino acid changes into a full-length spike (FL-S-2P) ectodomain representative of most approved vaccine antigens. These amino acid changes can be incorporated into the FL-S-2P protein without negatively effecting expression or stability. Furthermore, the amino acid changes improved functional antibody titers in both mice and monkeys following vaccination. These amino acid changes could increase the duration of protection conferred by most COVID-19 vaccines.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Published by Elsevier B.V.)
References: NPJ Vaccines. 2023 Feb 18;8(1):20. (PMID: 36808125)
Vaccines (Basel). 2023 Dec 28;12(1):. (PMID: 38250850)
MMWR Morb Mortal Wkly Rep. 2023 Jun 02;72(22):601-605. (PMID: 37262007)
N Engl J Med. 2022 Apr 21;386(16):1532-1546. (PMID: 35249272)
Nucleic Acids Res. 2003 Jul 1;31(13):3784-8. (PMID: 12824418)
Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089)
NPJ Vaccines. 2020 Sep 28;5:91. (PMID: 33083026)
Cell Rep. 2023 Mar 28;42(3):112266. (PMID: 36943870)
Viruses. 2021 May 12;13(5):. (PMID: 34065987)
Science. 2013 Nov 1;342(6158):592-8. (PMID: 24179220)
NPJ Vaccines. 2021 Aug 16;6(1):104. (PMID: 34400651)
Science. 2020 Mar 13;367(6483):1260-1263. (PMID: 32075877)
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357. (PMID: 28807998)
Cell. 2021 Apr 1;184(7):1821-1835.e16. (PMID: 33667349)
Nat Commun. 2019 Sep 24;10(1):4328. (PMID: 31551421)
Acta Crystallogr D Biol Crystallogr. 2006 Oct;62(Pt 10):1243-50. (PMID: 17001101)
Nature. 2020 Aug;584(7821):450-456. (PMID: 32698192)
Cell. 2022 Feb 3;185(3):467-484.e15. (PMID: 35081335)
Proc Natl Acad Sci U S A. 2021 Dec 14;118(50):. (PMID: 34876520)
Nat Commun. 2023 Sep 2;14(1):5345. (PMID: 37660103)
Nat Rev Immunol. 2022 Jan;22(1):57-65. (PMID: 34876702)
Nat Commun. 2022 Oct 6;13(1):5888. (PMID: 36202833)
Lancet Microbe. 2023 May;4(5):e309-e318. (PMID: 36963419)
NPJ Vaccines. 2023 Aug 4;8(1):108. (PMID: 37542029)
PLoS Pathog. 2024 Mar 4;20(3):e1011879. (PMID: 38437239)
Immunity. 2023 Feb 14;56(2):433-443.e5. (PMID: 36792576)
Sci Adv. 2022 Sep 16;8(37):eabq8276. (PMID: 36103542)
Lancet Infect Dis. 2022 Sep;22(9):1293-1302. (PMID: 35753318)
Nature. 2021 Aug;596(7871):276-280. (PMID: 34237773)
Sci Adv. 2023 Jun 9;9(23):eadg0330. (PMID: 37285422)
Science. 2021 Oct 22;374(6566):472-478. (PMID: 34554826)
N Engl J Med. 2021 Aug 12;385(7):585-594. (PMID: 34289274)
mBio. 2021 Mar 2;12(2):. (PMID: 33653892)
Sci Transl Med. 2021 Aug 18;13(607):. (PMID: 34315825)
N Engl J Med. 2021 Oct 14;385(16):1474-1484. (PMID: 34320281)
Science. 2020 Aug 7;369(6504):643-650. (PMID: 32540902)
معلومات مُعتمدة: ZIA AI001253 United States ImNIH Intramural NIH HHS; ZIA AI001262 United States ImNIH Intramural NIH HHS
المشرفين على المادة: 0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)
0 (COVID-19 Vaccines)
0 (Antibodies, Neutralizing)
0 (Antibodies, Viral)
تواريخ الأحداث: Date Created: 20240620 Date Completed: 20240715 Latest Revision: 20240717
رمز التحديث: 20240717
مُعرف محوري في PubMed: PMC11250568
DOI: 10.1016/j.antiviral.2024.105937
PMID: 38901738
قاعدة البيانات: MEDLINE
الوصف
تدمد:1872-9096
DOI:10.1016/j.antiviral.2024.105937